StageAcquired | Acquired
About Novum Pharmaceutical Research Services
Novum Pharmaceutical Research is a full-service CRO that conducts studies across multiple therapeutic areas and has developed long-standing relationships with a range of global sponsors who rely on its early phase research and clinical trial management expertise.
Missing: Novum Pharmaceutical Research Services's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Novum Pharmaceutical Research Services's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Novum Pharmaceutical Research Services News
Jul 21, 2020
Novum Expands North American Services With Consolidation Of A Canadian Clinical Facility PITTSBURGH, July 21, 2020 /PRNewswire/ -- Novum Pharmaceutical Research Services announced today an expansion of its services in North America. Author: Jul 21, 2020 10:14 AM EDT PITTSBURGH, July 21, 2020 /PRNewswire/ -- Novum Pharmaceutical Research Services announced today an expansion of its services in North America. Novum, one of the world's leading Contract Research Organizations (CRO) for almost fifty years, has consolidated Lambda Therapeutic Research's Toronto, Canada clinic and bioanalytical laboratory into Novum operations. This follows the 2019 acquisition of Novum by Lambda. The enhanced Novum organization will serve global clients throughout its operations in Pennsylvania, North Dakota, Nevada and Toronto, Canada. The Canadian site, which was founded in 2010, offers additional capacity to provide clinical services including Phase I (First-in-Human), Pharmacokinetics (PK), Pharmacodynamic (PD), Drug-Drug Interaction studies (DDI), Dose Escalation (SAD/MAD), Safety, Tolerability, Dose Ranging, and Patient PK studies. With state-of-the-art instrumentation, Novum Canada's bioanalytical lab has developed over 400 assays involving small and large molecules in its GLP compliant facility. Novum Canada's scientists routinely develop and validate methods and analyze over 15,000 samples a month, including proprietary methods for NCE and generic molecules with sub picogram detection, endogenous, chiral and hormonal assays. For additional information, prospective customers can visit www.novumprs.com , email Tausif Monif, President, Global Operations at email@example.com , or email Novum CEO Christopher H. Chamberlain at firstname.lastname@example.org . About Novum Pharmaceutical Research ServicesA leading Contract Research Organization (CRO) since 1972, Novum has been considered one of the world's leaders in the conduct of clinical trials, from First in Human studies to Late Phase Research requiring patient populations across multiple therapeutic areas. Novum provides bioanalytical services and full-service scientific support in medical writing and statistical analysis. The company is headquartered in Pittsburgh, Pennsylvania with operations in Toronto, North Dakota and Nevada. For more information, visit www.novumprs.com . View original content: http://www.prnewswire.com/news-releases/novum-expands-north-american-services-with-consolidation-of-a-canadian-clinical-facility-301096344.html
Novum Pharmaceutical Research Services Frequently Asked Questions (FAQ)
Where is Novum Pharmaceutical Research Services's headquarters?
Novum Pharmaceutical Research Services's headquarters is located at 225 W. Station Square Drive, Pittsburgh.
What is Novum Pharmaceutical Research Services's latest funding round?
Novum Pharmaceutical Research Services's latest funding round is Acquired.
Who are the investors of Novum Pharmaceutical Research Services?
Investors of Novum Pharmaceutical Research Services include Lambda Therapeutic Research.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.